中國生物製藥(01177.HK)組合營開發抗腫瘤項目
中國生物製藥(01177.HK)公布,附屬正大天晴與中山康方生物醫藥成立合營,共同開發重組人源化抗PD-1單克隆抗體AK105項目,並全力推動該藥物的註冊上市及產業化進程。
合營註冊資本6.89億人民幣,雙方分別持股50%。其中,正大天晴將以現金出資近3.45億人民幣,康方生物將以其AK105項目的知識產權和相關技術的全部權益作為無形資產出資。
AK105是前期由康方生物自主研發的重組人源化抗 PD-1 單克隆抗體,項目已完成在澳洲的I期爬坡試驗和在中國的I期臨床試驗,顯示了穩定的藥代動力學特徵和可喜的初步抗腫瘤有效性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.